Drug Profile
ONO 2952
Alternative Names: ONO-2952Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ono Pharmaceutical
- Class Irritable bowel syndrome therapies
- Mechanism of Action TSPO protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Irritable bowel syndrome
Most Recent Events
- 02 Feb 2016 Phase-II development is ongoing in USA
- 16 Feb 2015 Ono Pharmaceutical terminates a phase II trial for Irritable bowel syndrome (Diarrhoea predominant) in USA (NCT01887002)
- 01 Jul 2014 Ono Pharmaceutical completes the RESTORE phase II trial in Irritable bowel syndrome (Diarrhoea predominant) in USA (NCT01844180)